Tumor-associated Mucin 1 glyco-epitope (TA-MUC1) (TA-MUC1)

Tumor-associated Mucin 1 (TA-MUC1) glyco-epitope is a neoantigenic structure formed by the aberrant O-glycosylation of the Mucin 1 protein in malignant cells (Kufe, 2009, Nature Reviews Cancer). In healthy tissues, MUC1 is a heavily glycosylated transmembrane protein that protects the apical surface of epithelial cells; however, in cancer, the glycosylation process is disrupted, leading to the expression of truncated carbohydrate chains like the Tn and sialyl-Tn antigens (Beatson et al., 2016, PLoS ONE). These changes expose the protein's tandem repeat peptide backbone, creating a unique glyco-epitope that is highly specific to tumor cells and largely absent in normal tissues. TA-MUC1 plays a critical role in oncogenesis by promoting cell survival, metabolic reprogramming, and immune evasion through interactions with receptors like Siglec-9 (Nath & Mukherjee, 2014, Trends in Cancer). Because of its high tumor specificity and prevalence across various adenocarcinomas, it is a primary target for monoclonal antibodies, vaccines, and CAR-T cell therapies (Poseida Therapeutics, 2023; Glycotope, 2022). Current clinical efforts focus on overcoming the challenges of the immunosuppressive tumor microenvironment and the potential for antigen shedding which can interfere with drug binding.

Other names

Cancer-associated Mucin 1Tumor-specific Mucin 1Tn-MUC1Sialyl-Tn-MUC1MUC1 glycoformMucin 1, cell surface associated

Drugs targeting the TA-MUC1 glyco-epitope typically function by binding to the specific junction of the truncated glycan (such as Tn or STn antigens) and the MUC1 tandem repeat peptide core. This binding can trigger antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) in the case of monoclonal antibodies, or direct cytotoxic T-lymphocyte activity when targeted by CAR-T cells (Nath & Mukherjee, 2014, Trends in Cancer; Poseida Therapeutics, 2023).